000162694 001__ 162694
000162694 005__ 20230915092401.0
000162694 0247_ $$2doi$$a10.1038/s42003-021-02635-8
000162694 0247_ $$2pmid$$apmid:34545200
000162694 0247_ $$2pmc$$apmc:PMC8452639
000162694 0247_ $$2altmetric$$aaltmetric:113742287
000162694 037__ $$aDZNE-2021-01351
000162694 041__ $$aEnglish
000162694 082__ $$a570
000162694 1001_ $$00000-0002-5464-3779$$aWright, Sukhvir K$$b0
000162694 245__ $$aMultimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis.
000162694 260__ $$aLondon$$bSpringer Nature$$c2021
000162694 3367_ $$2DRIVER$$aarticle
000162694 3367_ $$2DataCite$$aOutput Types/Journal article
000162694 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655731085_9505
000162694 3367_ $$2BibTeX$$aARTICLE
000162694 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162694 3367_ $$00$$2EndNote$$aJournal Article
000162694 500__ $$aCC BY
000162694 520__ $$aSeizures are a prominent feature in N-Methyl-D-Aspartate receptor antibody (NMDAR antibody) encephalitis, a distinct neuro-immunological disorder in which specific human autoantibodies bind and crosslink the surface of NMDAR proteins thereby causing internalization and a state of NMDAR hypofunction. To further understand ictogenesis in this disorder, and to test a potential treatment compound, we developed an NMDAR antibody mediated rat seizure model that displays spontaneous epileptiform activity in vivo and in vitro. Using a combination of electrophysiological and dynamic causal modelling techniques we show that, contrary to expectation, reduction of synaptic excitatory, but not inhibitory, neurotransmission underlies the ictal events through alterations in the dynamical behaviour of microcircuits in brain tissue. Moreover, in vitro application of a neurosteroid, pregnenolone sulphate, that upregulates NMDARs, reduced established ictal activity. This proof-of-concept study highlights the complexity of circuit disturbances that may lead to seizures and the potential use of receptor-specific treatments in antibody-mediated seizures and epilepsy.
000162694 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000162694 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162694 650_2 $$2MeSH$$aAnimals
000162694 650_2 $$2MeSH$$aAnti-N-Methyl-D-Aspartate Receptor Encephalitis: chemically induced
000162694 650_2 $$2MeSH$$aAutoantibodies: adverse effects
000162694 650_2 $$2MeSH$$aDisease Models, Animal
000162694 650_2 $$2MeSH$$aMale
000162694 650_2 $$2MeSH$$aRats
000162694 650_2 $$2MeSH$$aRats, Wistar
000162694 650_2 $$2MeSH$$aSynaptic Transmission
000162694 7001_ $$00000-0002-0316-5818$$aRosch, Richard E$$b1
000162694 7001_ $$00000-0003-3317-9433$$aWilson, Max A$$b2
000162694 7001_ $$aUpadhya, Manoj A$$b3
000162694 7001_ $$00000-0002-0363-627X$$aDhangar, Divya R$$b4
000162694 7001_ $$aClarke-Bland, Charlie$$b5
000162694 7001_ $$aWahid, Tamara T$$b6
000162694 7001_ $$aBarman, Sumanta$$b7
000162694 7001_ $$aGoebels, Norbert$$b8
000162694 7001_ $$0P:(DE-2719)2811468$$aKreye, Jakob$$b9$$udzne
000162694 7001_ $$0P:(DE-2719)2810931$$aPrüß, Harald$$b10$$udzne
000162694 7001_ $$aJacobson, Leslie$$b11
000162694 7001_ $$00000-0002-6183-4493$$aBassett, Danielle S$$b12
000162694 7001_ $$aVincent, Angela$$b13
000162694 7001_ $$00000-0002-5038-5258$$aGreenhill, Stuart D$$b14
000162694 7001_ $$00000-0003-1281-9008$$aWoodhall, Gavin L$$b15
000162694 773__ $$0PERI:(DE-600)2919698-X$$a10.1038/s42003-021-02635-8$$gVol. 4, no. 1, p. 1106$$n1$$p1106$$tCommunications biology$$v4$$x2399-3642$$y2021
000162694 8564_ $$uhttps://pub.dzne.de/record/162694/files/DZNE-2021-01351.pdf$$yOpenAccess
000162694 8564_ $$uhttps://pub.dzne.de/record/162694/files/DZNE-2021-01351.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162694 909CO $$ooai:pub.dzne.de:162694$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162694 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811468$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000162694 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000162694 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000162694 9141_ $$y2021
000162694 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-06-15
000162694 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-06-15
000162694 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-06-15
000162694 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-06-15
000162694 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-06-15
000162694 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162694 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-06-15
000162694 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCOMMUN BIOL : 2021$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-10-13T14:52:02Z
000162694 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-10-13T14:52:02Z
000162694 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-10-13T14:52:02Z
000162694 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2022-11-12
000162694 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCOMMUN BIOL : 2021$$d2022-11-12
000162694 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Enzephalopathies$$x0
000162694 980__ $$ajournal
000162694 980__ $$aVDB
000162694 980__ $$aUNRESTRICTED
000162694 980__ $$aI:(DE-2719)1810003
000162694 9801_ $$aFullTexts